{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:15:53Z","timestamp":1793103353041,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recent studies suggest that individuals with inflammatory bowel disease (IBD) are at a significantly higher risk of developing non-alcoholic fatty liver disease (NAFLD) compared to the general populace. Furthermore, the coexistence of NAFLD is likely to intensify the overall health impact experienced by individuals with IBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This review aims to assess the prevalence of NAFLD and its associated risk factors in IBD patients through systematic analysis. We searched for relevant literature in the PubMed and Medline databases from January 2014 to April 2024 and conducted a meta-analysis to quantitatively synthesize eligible studies, the search criteria were designed to encompass a broad spectrum of research investigating the link between IBD and NAFLD. After completing the literature search, a meticulous screening process was undertaken to filter out studies that did not meet the predefined eligibility criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The analysis encompassed 26 studies, representing a cohort of over 429,550 IBD patients. Our study indicated that the aggregate incidence of NAFLD within this IBD population was 34%, with a 95% confidence interval ranging from 27% to 41%. Additionally, the research highlighted that the likelihood of NAFLD onset is increased in IBD patients with a prolonged illness duration, obesity, and those presenting metabolic syndrome characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The incidence of NAFLD among individuals with IBD notably exceeds that observed in the general populace. This heightened prevalence correlates with factors such as disease severity, metabolic risk profiles, and the impact of pharmacological interventions. Further research is needed to further elucidate these risk factors and establish screening recommendations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1517462","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:36:11Z","timestamp":1752644171000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence of non-alcoholic fatty liver disease among inflammatory bowel disease patients: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuyang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia.","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.3390\/ijerph18105227","article-title":"Non-alcoholic fatty liver disease: Metabolic, genetic, epigenetic and environmental risk factors.","volume":"18","author":"Juanola","year":"2021","journal-title":"Int J Environ Res Public Health."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2007.02.009","article-title":"Epidemiology and natural history of NAFLD and NASH.","volume":"11","author":"Ong","year":"2007","journal-title":"Clin Liver Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates.","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: Updated analysis of indications for liver transplant and ethnic and gender variances.","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"891410","DOI":"10.3389\/fphar.2022.891410","article-title":"Mendelian randomization rules out causation between inflammatory bowel disease and non-alcoholic fatty liver disease.","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-pathol-012615-044152","article-title":"Genetics and pathogenesis of inflammatory bowel disease.","volume":"11","author":"Liu","year":"2016","journal-title":"Annu Rev Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41419-017-0124-2","article-title":"Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease.","volume":"9","author":"Sartini","year":"2018","journal-title":"Cell Death Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0206450","DOI":"10.1371\/journal.pone.0206450","article-title":"Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study.","volume":"13","author":"Adams","year":"2018","journal-title":"PLoS One."},{"key":"B12","doi-asserted-by":"publisher","first-page":"113331","DOI":"10.1016\/j.biopha.2022.113331","article-title":"Recent advances in lean NAFLD.","volume":"153","author":"Xu","year":"2022","journal-title":"Biomed Pharmacother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/ibd\/izz043","article-title":"Systematic review with meta-analysis: Epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease.","volume":"25","author":"Zou","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128\u22c59 million children, adolescents, and adults.","volume":"390","year":"2017","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: Global epidemiology and pathogenesis.","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ibd.21669","article-title":"Changing shape of disease: Nonalcoholic fatty liver disease in Crohn\u2019s disease-a case series and review of the literature.","volume":"18","author":"McGowan","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3109\/00365521.2014.921326","article-title":"National trends and inpatient outcomes of inflammatory bowel disease patients with concomitant chronic liver disease.","volume":"49","author":"Nguyen","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.3748\/wjg.v22.i34.7727","article-title":"Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.","volume":"22","author":"Chao","year":"2016","journal-title":"World J Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","article-title":"Obesity in IBD: Epidemiology, pathogenesis, disease course and treatment outcomes.","volume":"14","author":"Singh","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.3390\/ijms19082199","article-title":"Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-\u03b1 on the liver.","volume":"19","author":"Lopetuso","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1016\/j.crohns.2012.09.009","article-title":"High prevalence of overweight and obesity in adults with Crohn\u2019s disease: Associations with disease and lifestyle factors.","volume":"7","author":"Nic Suibhne","year":"2013","journal-title":"J Crohns Colitis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/MIB.0000000000001085","article-title":"Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease.","volume":"23","author":"Glassner","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejim.2023.10.019","article-title":"Crohn\u2019s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease.","volume":"120","author":"Mart\u00ednez-Dom\u00ednguez","year":"2024","journal-title":"Eur J Intern Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/ibd\/izy051","article-title":"Nonalcoholic fatty liver disease in inflammatory bowel disease: Prevalence and risk factors.","volume":"24","author":"Principi","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.3748\/wjg.v26.i46.7367","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis.","volume":"26","author":"Hoffmann","year":"2020","journal-title":"World J Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/ibd\/izy200","article-title":"Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: A cohort study using transient elastography.","volume":"25","author":"Saroli Palumbo","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00384-021-04065-8","article-title":"Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up.","volume":"37","author":"van Lingen","year":"2022","journal-title":"Int J Colorectal Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1007\/s10620-020-06588-6","article-title":"Nonalcoholic fatty liver disease is common in IBD patients however progression to hepatic fibrosis by noninvasive markers is rare.","volume":"66","author":"Ritaccio","year":"2021","journal-title":"Dig Dis Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.humpath.2017.09.008","article-title":"Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease.","volume":"69","author":"Bosch","year":"2017","journal-title":"Hum Pathol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1159\/000506938","article-title":"Sarcopenia is a new risk factor of nonalcoholic fatty liver disease in patients with inflammatory bowel disease.","volume":"38","author":"Kang","year":"2020","journal-title":"Dig Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.5009\/gnl220409","article-title":"Hepatic steatosis but not fibrosis is independently associated with poor outcomes in patients with inflammatory bowel disease.","volume":"18","author":"Hyun","year":"2024","journal-title":"Gut Liver."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1097\/MIB.0000000000000832","article-title":"Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease.","volume":"22","author":"Bessissow","year":"1937","journal-title":"Inflamm Bowel Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1097\/CM9.0000000000002859","article-title":"Non-alcoholic fatty liver degree and long-term risk of incident inflammatory bowel disease: A large-scale prospective cohort study.","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin Med J (Engl)."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/j.crohns.2012.10.015","article-title":"Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.","volume":"7","author":"Sourianarayanane","year":"2013","journal-title":"J Crohns Colitis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.20524\/aog.2019.0371","article-title":"Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department.","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann Gastroenterol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.20524\/aog.2019.0405","article-title":"High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy.","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.14309\/01.ajg.0000798780.14901.4e","article-title":"P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.","volume":"116","author":"Lopes","year":"2021","journal-title":"Am J Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.3390\/jcm11092623","article-title":"Hepatic steatosis and fibrosis in chronic inflammatory bowel disease.","volume":"11","author":"Veltkamp","year":"2022","journal-title":"J Clin Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.3390\/jcm11195959","article-title":"Screening for liver steatosis and fibrosis in patients with inflammatory bowel disease using vibration controlled transient elastography with controlled attenuation parameter.","volume":"11","author":"Trifan","year":"2022","journal-title":"J Clin Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1093\/ecco-jcc\/jjx002.448","article-title":"P323 Fatty liver assessment in inflammatory bowel disease patients using controlled attenuation parameter.","volume":"11","author":"Balaban","year":"2017","journal-title":"J Crohns Colitis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12876-019-0967-3","article-title":"Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: A referral center study.","volume":"19","author":"Fousekis","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"B42","first-page":"10633","article-title":"High incidence of non-alcoholic fatty liver disease in patients with Crohn\u2019s disease but not ulcerative colitis.","volume":"10","author":"Li","year":"2017","journal-title":"Int J Clin Exp Pathol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.3748\/wjg.v25.i37.5676","article-title":"Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.","volume":"25","author":"Magr\u00ec","year":"2019","journal-title":"World J Gastroenterol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/hepr.12828","article-title":"Significance of non-alcoholic fatty liver disease in Crohn\u2019s disease: A retrospective cohort study.","volume":"47","author":"Sagami","year":"2017","journal-title":"Hepatol Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/ibd\/izy128","article-title":"IRGM gene variants modify the relationship between visceral adipose tissue and NAFLD in patients with crohn\u2019s disease.","volume":"24","author":"Simon","year":"2018","journal-title":"Inflamm Bowel Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1517462\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:36:12Z","timestamp":1752644172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1517462\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":45,"alternative-id":["10.3389\/fmed.2025.1517462"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1517462","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"article-number":"1517462"}}